ABSTRACT
INTRODUCTION
During the last 15 years, fetal cardiac intervention has been used as a treatment for fetal aortic stenosis, with the goal of halting disease progression in utero and avoiding or reducing the need for single ventricle palliation 1 -3 . However, severe aortic stenosis is not the only route to developing left-sided cardiac structures that are too small to support systemic circulation. There is a group of fetuses with hypoplasia of multiple left heart structures, in which aortic stenosis is not the primary lesion, but coarctation of the aorta and an apex-forming left ventricle are almost universally present. We term this lesion left heart hypoplasia (LHH), although other frequently used names for this entity are borderline left ventricle, hypoplastic left heart complex or Shone complex variant 4, 5 . This group almost universally requires neonatal intervention and is at risk of requiring single ventricle palliation 6 . However, these fetuses are not candidates for fetal interventions that are currently available.
The fetal pulmonary circulation is highly sensitive to small changes in pulmonary arterial oxygen saturation and tension 7 . It has been shown that when supplemental oxygen is provided to gravid women, termed maternal hyperoxygenation, there is an increase in fetal pulmonary blood flow resulting in greater venous return to the left heart, and this response increases with gestational age 8 -11 . One study showed a significant increase in blood oxygen level in fetuses exposed to maternal hyperoxygenation, although the evidence is not uniform 12, 13 . There is also limited evidence that intermittent chronic maternal hyperoxygenation (CMH) may improve growth of the left heart in fetuses with LHH 14, 15 . Our hypothesis was that fetuses with LHH who undergo CMH therapy will have improved growth of the mitral valve and aortic valve annuli compared with similar fetuses without CMH. We aimed to: (i) quantify the effect of acute maternal hyperoxygenation (AMH) on aortic flow as a percentage of combined cardiac output in fetuses with LHH; (ii) determine the magnitude of effect of CMH on growth of mitral and aortic valve annular dimensions when compared with historical controls; (iii) determine whether CMH is safe for mothers and fetuses; and (iv) determine whether daily administration of oxygen to pregnant mothers is feasible and tolerated by mothers.
PATIENTS AND METHODS
The study was designed as a pilot interventional study for determination of feasibility, using historical controls for comparison. We started with a small 1-year pilot trial to determine whether the chosen daily dose, duration of therapy and method of delivery appeared to be feasible, or if alterations in the regimen would be suggested by the data, prior to planning a larger randomized trial. This project was approved by the Institutional Review Board for Baylor College of Medicine and Affiliated Hospitals (Protocol Number H-33802).
Inclusion criteria were gravidae with fetal LHH, defined as the sum of aortic and mitral valve annular Z-scores of < −4.5, as well as flow reversal in the aortic arch and left-to-right or bidirectional atrial-level shunting. These criteria were chosen as these variables have high specificity for the need for neonatal intervention 16, 17 . We excluded patients with fetal hypoplastic left heart syndrome (HLHS) (defined as severe mitral stenosis or atresia plus severe aortic stenosis or atresia with a severely hypoplastic non-apex-forming left ventricle), severe valvular aortic stenosis, extracardiac fetal anomalies or significant maternal comorbidities. These inclusion and exclusion criteria were used for our prospective and control patients. Gravidae were enrolled prospectively into the intervention group between February 2014 and January 2015. The control group comprised gravidae with a history of fetal LHH cared for at our institution from July 2012 to October 2014 who did not undergo CMH. Gravidae were enrolled after 26 weeks' gestation, as fetal vasoactive response to oxygen increases dramatically during this period 10 . Controls were the last nine consecutive gravidae who met the inclusion criteria. Case-by-case matching by gestational age and annular size was not performed, as this would require drawing a subset of controls from a much larger number of fetuses with LHH. This strategy would have resulted in the control group being cared for over a much broader historical time frame than the intervention patients, and reaching back to years with lower quality fetal echocardiographic images and possibly different surgical management.
Prior to enrollment in the prospective intervention group, gravidae were evaluated by an oxygen challenge to determine whether the fetus would respond to AMH. All mothers who met the inclusion criteria were offered enrollment. The evaluation started with a full fetal echocardiogram in room air. This was followed by an oxygen challenge with repeat assessment of aortic and pulmonary artery flow after 10 min of AMH at 8 L/min 100% fraction of inspired oxygen via a non-rebreather face mask. Responders were defined as fetuses with a greater than 10% increase in percent aortic output with AMH. Percent aortic output was calculated as aortic output/aortic + pulmonary output, with outputs calculated using the following formula: semilunar valve velocity time integral × cross-sectional area of semilunar valve annulus (π/4 × annular diameter 2 ) × heart rate (beats/min) 18 . Responders were then offered enrollment in the intervention group of the study. The historical controls were not evaluated for a response to oxygen.
The intervention was intermittent CMH therapy consisting of a goal of ≥ 8 h daily of oxygen at 8-9 L/min 100% fraction of inspired oxygen for the remainder of gestation. To ensure an adequate and standardized oxygen delivery, maternal arterial partial pressure of oxygen (PaO 2 ) was measured by arterial blood gas assessment on the first CMH day after at least 1 h of supplemental oxygen at 8 L/min with a goal PaO 2 of 250 mmHg. For mothers with a PaO 2 of < 250 mmHg, the flow was increased to 9 L/min. CMH gravidae were sent home with an oxygen condenser and a non-rebreather mask. Mothers logged their hours on oxygen and were encouraged to continue CMH therapy as long as possible each day, with the understanding that oxygen therapy might not be possible during bathing, meals and work. The mothers were followed with regular surveillance visits that included five fetal echocardiograms during the first week and then weekly thereafter until delivery. The purpose of the close observation by fetal echocardiogram was to assess for restriction of the ductus arteriosus and to ensure no deterioration in cardiovascular status. After birth, all intervention and control patients were started on a prostaglandin infusion, underwent postnatal echocardiography and were treated as clinically indicated. Each intervention patient received a postnatal ophthalmologic examination during the perinatal hospitalization period, to assess for retinopathy, and were scheduled for neurodevelopmental follow-up at 6 and 12 months of age.
All fetal echocardiograms were conducted by an American Registry for Diagnostic Medical Sonography certified fetal sonographer with > 7 years of experience or a fetal cardiologist. Measurements were performed in a blinded-to-study manner. Measurements were made by one of the aforementioned fetal sonographers (M.N. and D.K.F.) in a blinded manner, using deidentified echocardiograms, which were only reidentified for analysis. Deidentification included removal of name, medical record number, date of study and gestational age. All deidentified studies were provided together in a random order to the sonographers for measurement, so that no date-based identification could be made. Quality was checked by two fetal cardiologists (S.A.Mo. and J.B.). Fetal Z-scores based on gestational age were calculated using available normative data 19 .
Statistical analysis
Baseline characteristics were compared between the intervention and control groups using Wilcoxon rank-sum, chi-square and Fisher's exact test when appropriate. Comparisons of annular dimensions were performed using Student's t-test. Percent aortic cardiac output at baseline and after AMH were compared using Wilcoxon signed-rank analysis. Our primary outcomes were the safety and feasibility of CMH therapy, and the rate of fetal aortic and mitral annular growth. Longitudinal linear regression analysis with random intercepts was used, which accounts for the covariance between repeated measurements in the same fetus. Terms in the model were intervention (yes or no) and time (gestational age at the time of measurement). An interaction term for intervention and time was also used in the model, in order to be able to compare slopes of growth between the CMH group and controls with increasing gestational age. Mean slopes and confidence intervals were reported to assess effect estimates.
Annular sizes were chosen as the primary outcomes for the study in lieu of Z-scores given that fetal Z-scores are extrapolated from another equation, and are based on gestational age alone. Additionally, analyses comparing postnatal characteristics were performed using Wilcoxon rank-sum and Fisher's exact tests. Postnatal Z-scores were calculated based on infant body surface area using previously published methods 20 . A secondary analysis was performed comparing rates of growth by total days and daily hours on oxygen, to investigate whether there could be a dose effect. Interobserver variability was calculated comparing aortic and mitral annular diameters from 10 examinations by both fetal sonographers using the intraclass correlation coefficient. All analyses were performed using SAS, version 9.4 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Nine mothers were enrolled for CMH and nine were included as historical controls (Table 1 ). The two groups were similar, with no significant differences in gestational age, estimated fetal weight, and aortic and mitral valve dimensions at the first fetal echocardiogram ≥ 26 weeks (enrollment echocardiogram for CMH patients). Gestational age at CMH initiation ranged from 26 to 34 weeks. Figure 1 displays the results of the oxygen challenge in individual intervention patients. Table 2 displays results for the group as a whole. All gravidae in the prospective intervention group responded to the oxygen challenge. One mother failed to respond at 26 weeks' gestation but subsequently did so at 28 weeks' gestation on re-evaluation. Otherwise, there were no non-responders. Evaluating the group as a whole, aortic flow as a percent of combined cardiac output increased from a median of 20% at baseline to 26% after AMH, with a median percent change of 33% from baseline (P = 0.008). Pulmonary flow and combined cardiac output did not change significantly. Median number of hours per day on CMH therapy was 9.3 with a range of 6.5-14.6. Median number of days on oxygen was 48 with a range of 33-84. Median total hours on oxygen was 542 with a range of 292-1011.
Data from a total of 98 echocardiographic examinations were included in the longitudinal analysis. Fetuses undergoing CMH therapy underwent a median of nine (range, 4-12) fetal echocardiograms ≥ 26 weeks' gestation, whereas controls underwent a median of two (range, 2-3) echocardiograms ≥ 26 weeks' gestation. The intraclass correlation coefficient for measurements of aortic annulus was 0.965 and that for the mitral annulus was 0.881.
The regression lines for aortic and mitral annular growth in both groups are displayed in Figure 2 . The aortic valve (Figure 2b ) grew a mean of 0.13 ± 0.03 mm/week in the control group and 0.14 ± 0.03 mm/week in the CMH group (P = 0.75). The mitral valve (Figure 2d ) grew a mean of 0.14 ± 0.05 mm/week in the control group and 0.19 ± 0.05 mm/week in the CMH group (P = 0.33).
More total days on oxygen were not associated with greater growth of the aortic annulus (−0.01 ± 0.01 mm/week/extra 10 days, P = 0.24) or the mitral annulus (0.01 ± 0.02 mm/week/extra 10 days, P = 0.78). When investigating the relationship between daily hours and growth (Figure 3) , there was a pattern in which patients on greater than a mean of 9 h daily of oxygen (n = 6 patients) had faster aortic annular growth than the fetuses receiving < 9 h daily of oxygen (n = 3) (0.16 ± 0.03 vs 0.08 ± 0.02 mm/week, P = 0.014). This pattern was not present for the mitral annulus (0.19 ± 0.06 vs 0.20 ± 0.05 mm/week, P = 0.76). Figure 4 displays the aortic flow as a percent of combined cardiac output over time for both intervention 
Characteristic
Intervention (n = 9) Control (n = 9) P Data are given as mean ± SD, median (range) or n. *All control fetuses with right-to-left flow on the first fetal echocardiogram ≥ 26 weeks' gestation had either left-to-right flow (n = 2) or bidirectional flow (n = 2) on the following fetal echocardiogram. and controls. The intervention group had a higher mean aortic flow over the course of gestation compared with controls, although this was not significant (P = 0.58). Figure 5 displays the estimated fetal weight over time.
Mean estimated fetal weight gain was 204 ± 12 g/week in the CMH group and 213 ± 11 g/week in the controls (P = 0.47). Table 3 displays infant characteristics at birth. The values of all mean aortic Z-scores were greater in the CMH group than in controls, but there were large SDs in the small sample and no statistically significant differences between the groups. Note that no patient had more than mild mitral regurgitation on their initial postnatal echocardiogram. Table 3 also displays the surgical outcomes for the two groups. There were no patient deaths.
There were no fetal complications in the CMH cohort, including no evidence of ductal constriction. There were Data are given as median (range).
25 30
Gestational age (weeks) no major maternal complications; one mother on CMH developed epistaxis on the first day of therapy, which resolved with addition of a humidifier to the condensing unit. Thereafter, all units were paired with a humidifier. There was no evidence of retinopathy on ophthalmologic examinations, with each patient demonstrating complete retinal vascularization.
DISCUSSION
This analysis of pilot data in our initial feasibility study demonstrates that AMH increases aortic flow in fetuses with LHH, and that CMH therapy is safe and feasible. Although there were no significant differences in annular growth over the course of the study, this study was designed as a pilot with no sample size calculations and used a convenience sample over a given time interval (11 months), given no similar previous studies with control data.
This study provides effect estimates of CMH on aortic and mitral annular growth, as well as the difference in rate of growth based on number of hours per day on CMH. We found that the slopes of both aortic and mitral annular change were greater in CMH fetuses compared with controls, although the effect was not statistically significant, and in the fetuses with the greatest response the magnitude of the effect was still small (0.5 mm more growth in the aortic valve and 0.8 mm more growth in the mitral valve in fetuses with CMH therapy between 26 weeks and term). We noted that the rate of aortic annular growth was greater with more daily hours of oxygen, suggesting that perhaps future studies should investigate a longer daily duration of oxygen therapy.
Maternal hyperoxygenation has been used by obstetricians for over 25 years for treatment and risk stratification of multiple disease processes, although the overall evidence for its uses in these conditions is weak and it is not a widely accepted practice in obstetrics 8,21 -23 . AMH has been studied in fetal congenital heart disease. Rasanen et al. 10 authored one of the earliest studies on the hemodynamic effects of AMH, which showed a dramatically increased vasoreactive response after 26 weeks' gestation. Channing et al. 9 and Szwast et al. 11, 24 studied AMH as a risk stratification tool for patients with HLHS and restrictive or intact atrial septum and showed Data are given as mean ± SD or n.
improved left heart filling in patients with atrial septal aneurysm and 'brain-sparing' physiology in patients with HLHS. Borik et al. 13 in Toronto and Enzensberger et al. 25 in Germany have also assessed AMH as a therapeutic and diagnostic tool. There has been only one study of CMH, by Kohl 14 in Germany, which showed improved growth of hypoplastic cardiac structures.
Our study is the first to test the potential therapeutic benefit of CMH in a controlled manner. The findings support the previous findings of Kohl 14 , although our study has the additional strengths of a control group and a more homogeneous population at which to direct the therapy.
We found that CMH is feasible. No mother enrolled in the intervention group discontinued participation in the study, and all underwent CMH therapy until delivery. However, some mothers did find wearing the non-rebreather mask for many hours daily challenging, and this resulted in two mothers having mean daily hours on oxygen lower than the goal (8 h) of the study.
Given our results, we cannot claim that CMH in its current form should be used clinically. However, this study can serve as a building block for future investigations of CMH as a therapy for left heart growth or as therapy for brain immaturity seen in congenital heart disease, as some investigators have suggested 26 . Although fetal LHH is typically associated with isolated coarctation as a neonate, multiple studies have demonstrated that a proportion of these patients require single ventricle palliation, have multiple reoperations and are more likely to die in infancy and childhood 4, 17, 27, 28 . In patients with LHH undergoing only coarctation repair at birth, up to 24% require repeat surgical intervention on left heart structures 29, 30 . The choice of fetuses with LHH and not outright HLHS was based on the theory that fetuses with apex-forming left ventricles have greater growth potential of left-sided structures than those who have already developed endocardial fibroelastosis and/or have a shortened left ventricle. This has been clearly shown in the postnatal population 29, 31, 32 . The ultimate goal of fetal therapy for this population would be to eliminate or reduce the need for single ventricle palliation and for reoperation. This could potentially be accomplished if fetal growth of left-sided structures could be improved in utero.
We note that, although not a significant difference, estimated fetal weight gain and birth weight were slightly lower in the fetuses undergoing CMH therapy than in controls. Any future studies will need to investigate this in detail and be aware of a possible influence on fetal weight.
We have demonstrated that CMH can be initiated safely between the late second and early third trimester of gestation, and can be continued through the remainder of gestation without obvious deleterious effects to the mother or fetus. Although these results mirror those found in the literature 14, 23, 33 , our study is very small and continued rigorous monitoring of patients under similar protocols should be undertaken. Further, we have shown that CMH can be accomplished at home, requires few personnel to arrange and supervise, and entails no expensive equipment beyond that already used for standard care.
As this was a pilot study, we had small numbers, which underpowered the study to show statistical significance. We used a convenience sample of historical controls and not prospectively enrolled controls, which limits comparability of groups given unknown confounders. Fetuses undergoing CMH therapy underwent more fetal echocardiograms for analysis than did the control fetuses.
This resulted in narrower CIs of the mean slopes in the intervention group than in the control group. Finally, the members of the historical control group were not assessed for an acute response to oxygen, which limits our ability to fully compare the two groups.
In conclusion, this pilot study demonstrated that fetuses with LHH undergoing AMH have significantly increased aortic flow, and there are no significant evident maternal or fetal complications of CMH. Effect estimates of aortic and mitral annular growth in fetuses undergoing CMH compared with controls were positive, although no differences were statistically significant. Further, fetuses on CMH for more hours per day had greater aortic annular growth. Based on our findings, CMH therapy deserves further investigation as a low-risk intervention for fetal LHH.
